VITAL - VAP Prevention by BIP (Bactiguard Infection Protection) ETT Evac in Belgian ICUs (VITAL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04242706|
Recruitment Status : Recruiting
First Posted : January 27, 2020
Last Update Posted : January 27, 2020
|Condition or disease||Intervention/treatment||Phase|
|Ventilator-associated Pneumonia||Device: ETTEvac Device: BIP ETTEvac||Phase 4|
The aim of the study is to determine VAP (Ventilator Associated Pneumonia) baseline incidence in the ICU in patients receiving endotracheal tubes with evacuation lumen with and without Bactiguard Infection Protection (BIP) coating.
VAP is likely to occur in 10-20% of patients who are ventilated for at least 48 hours. These patients face a mortality risk estimated to be twice as high compared with similar ICU patients without VAP. Furthermore, VAP results in an average excess length of ICU stay with high hospital cost.
Bactiguard has developed an endotracheal tube coated with a thin layer of non-releasing metals (gold, silver and palladium) firmly attached to the surface. This Bactiguard coating is tissue friendly and aims to achieve an optimal combination of anti-infective properties to reduce biofilm formation, colonization and subsequent respiratory infection. Bactiguard coated urinary products have been on market since 1995 (initially in US, then also in Japan & Europe) and used in a large number of clinical studies and evaluations, showing reduction of urinary tract infections and also antibiotics use. A BIP ETT (without evacuation lumen) clinical safety and tolerability study was performed at Karolinska University Hospital during 20128. The study showed that BIP ETT is safe, well tolerable and performs well in clinical settings.
The present study of BIP ETT with evacuation lumen is randomized, prospective, controlled and blinded. All adult ICU patients hospitalized in the ICUs from two tertiary hospitals (i.e.: Centre Hospitalier Universitaire Sart Tilman Liège , Centre Hospitalier Chrétien de Liège) and considered to be ventilated for more than 24 hours will be eligible to participate in the study. 300 patients in total will be used to determine baselines levels (150 in each group).
The study tubes will be available not only in the ICUs but also in the emergency department, including the emergency vehicles, and in every hospital wards. The study tubes will not be available in the operating rooms except in the Post Anesthesia Care Units (PACU) and Recovery rooms.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||300 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||
Controlled study. Two interventions:
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Masking Description:||Blinded, the two devices have the same appearance.|
|Official Title:||VITAL - VAP Prevention in ICU by BACTIGUARD coAting of endotracheaL Tube|
|Actual Study Start Date :||November 5, 2018|
|Estimated Primary Completion Date :||September 1, 2020|
|Estimated Study Completion Date :||January 1, 2021|
Active Comparator: Control group
Endotracheal tube with evacuation lumen without Bactiguard coating.
Endotracheal tube with evacuation lumen without noble metal coating
Experimental: Experimental group
Endotracheal tube with evacuation lumen with Bactiguard coating.
Device: BIP ETTEvac
Endotracheal tube with evacuation lumen with noble metal coating
- VAP incidence [ Time Frame: Up to 28 days after inclusion ]Ventilator Associated Pneumonia incidence
- Nosocomial infections [ Time Frame: Up to 28 days after inclusion ]Incidence of any kind of nosocomial infection
- VAT incidence [ Time Frame: Up to 28 days after inclusion ]Ventilator Associated Tracheabronchitis incidence
- Antibiotics consumption [ Time Frame: Up to 28 days after inclusion ]
- Duration of ventilation [ Time Frame: Up to 28 days after inclusion ]Days of intubation with study tube
- Duration of ICU and hospital stay [ Time Frame: Up to 28 days after inclusion ]
- Mortality [ Time Frame: Up to 60 days after inclusion ]
- Tracheal bacterial colonization [ Time Frame: Up to 28 days after inclusion ]Incidence of tracheal bacterial colonization reaching a CFU Count 10^6 CFU/ml
- VAC and iVAC [ Time Frame: Up to 28 days after inclusion ]Ventilator associated Condition and infectious iVAC
- Evaluation of microbial data [ Time Frame: Up to 28 days of intubation after inclusion ]Amount and type of bacteria, resistance pattern
- Evaluation of durability of the coating metals at the surface during use [ Time Frame: Up to 28 days of intubation after inclusion ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04242706
|Contact: Benoît Misset, MD,Prof.||+32-4-366 74 email@example.com|
|Contact: Pierre Damas, MD,Prof.||+32-485-38 00 firstname.lastname@example.org|
|Centre Hospitalier Chrétien de Liège and Centre Hospitalier Chrétien (CHC Clinique de l'Espérance)||Recruiting|
|Contact: Philippe Devos, MD 04 224 81 11 ext +32 email@example.com|
|Centre Hospitalier Universitaire Sart Tilman Liège||Recruiting|
|Liège, Belgium, B-4000|
|Contact: Benoît Misset, MD, Prof 04-366 74 95 ext +32 firstname.lastname@example.org|
|Contact: Pierre Damas 04-85-38 00 93 ext +32 email@example.com|
|Principal Investigator:||Benoit Misset, MD,Prof.||CHU, Liege; Belgium|